Working… Menu
Trial record 1 of 1 for:    Onc 208
Previous Study | Return to List | Next Study

NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01369420
Recruitment Status : Completed
First Posted : June 9, 2011
Last Update Posted : November 8, 2016
Information provided by (Responsible Party):
Angiodynamics, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma. Safety will be reviewed by means of analysis of adverse events, including serious adverse events, laboratory data, physician exam findings, and vital signs.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Device: NanoKnife Low Energy Direct Current (LEDC) System Ablation Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety Evaluation of the NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer - A Pilot Study
Study Start Date : May 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Intervention Details:
  • Device: NanoKnife Low Energy Direct Current (LEDC) System Ablation
    90 pulses of 70 microseconds each in duration will be administered per electrode pair.
    Other Names:
    • ◦ Low Energy Direct Current (LEDC) System
    • ◦ HVP01 Electroporation System
    • ◦ NanoKnife LEDC System
    • ◦ NanoKnife IRE System
    • ◦ Non-Thermal Irreversible Eletroporation (NTIRE) System
    • ◦ Angiodynamics IRE System
    • ◦ Non-Thermal Ablation

Primary Outcome Measures :
  1. Safety [ Time Frame: 90 days ]
    • reported adverse events and adverse effects/events (serious and non serious),
    • unanticipated adverse events and device complaints,
    • safety laboratory tests (hematology, chemistry, amylase, lipase),
    • vital signs,
    • physical findings (including symptoms, vital signs and weight changes)

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: 90 days ]

    Evaluation of short term efficacy based upon tumor evaluation and symptomatic response as defined by:

    • imaging will be used to evaluate changes in tumor size in addition to evaluating the completeness of ablation,
    • tumor evaluation by evaluating changes in CA-19-9 marker,
    • symptomatic changes of quality of life questionnaires,
    • physician assessment of the performance status of the subject,
    • pain assessment and subject analgesic consumption,
    • assessment of tumor for downstaging to resectability at the time of imaging

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. male or female
  2. >/= 18 years of age
  3. meets criteria for locally advanced unresectable pancreatic adenocarcinoma, as radiographically proven pancreatic cancer as determined by a surgical oncologist via pancreatic CT or who were initially thought to be resectable; however at the time of surgery were upstaged to unresectability, via direct visualization
  4. tumor size must be < 4 cm and must be measurable
  5. must have an INR <1.5
  6. must be unresponsive to chemotherapy as demonstrated with either CT or MR imaging and not have taken any chemotherapy agents within 14 days of treatment with the NanoKnife LEDC System
  7. are willing and able to comply with the protocol requirements
  8. are able to comprehend and willing to sign an Informed Consent Form (ICF)

Exclusion Criteria:

  1. a baseline creatinine reported as > 2.0 mg/dL
  2. have any reported baseline lab values with a grade 3 or 4 toxicity as defined by the CTCAE Version 3.0
  3. inability to stop antiplatelet and Coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System
  4. known history of contrast allergy that cannot be medically managed
  5. known hypersensitivity to the metal in the electrodes (stainless steel 304L) that cannot be medically managed
  6. unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc)
  7. women who are pregnant or currently breast feeding
  8. women of childbearing potential who are not utilizing an acceptable method of contraception
  9. have taken an investigational agent within 30 days of visit 1
  10. have implanted cardiac pacemakers or defibrillators
  11. have implanted electronic devices or implants with metal parts in the immediate vicinity of a lesion
  12. have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation)
  13. have a recent history of myocardial infarction (within the past 2 months)
  14. have Q-T intervals greater than 550 ms unless treated with an Accysync Model 72 synchronization system controlling the NanoKnife system's output pulses.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01369420

Layout table for location information
Policlinico "G.B. Rossi", University of Verona, Department of Surgery
Verona, Italy, 37134
Sponsors and Collaborators
Angiodynamics, Inc.
Layout table for investigator information
Principal Investigator: Claudio Bassi, M.D. Policlinico "G.B. Rossi", University of Verona, Department of Surgery

Layout table for additonal information
Responsible Party: Angiodynamics, Inc. Identifier: NCT01369420    
Other Study ID Numbers: ONC-208
First Posted: June 9, 2011    Key Record Dates
Last Update Posted: November 8, 2016
Last Verified: November 2016
Keywords provided by Angiodynamics, Inc.:
locoregional cancer therapy
pancreatic cancer
unresectable pancreatic cancer
pancreatic adenocarcinoma
locally advanced, unresectable pancreatic cancer
pancreatic cancer tumor ablation
NanoKnife tumor ablation for pancreatic cancer
NanoKnife LEDC system tumor ablation
Non thermal ablation
Irreversible electroporation for pancreatic cancer treatment
IRE for unresectable pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases